CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2010-03-01 | Koya Keizo Sr. VP, Drug Development | Grant or award | +8,224 | 51,269 | ||
| 2010-03-01 | Koya Keizo Sr. VP, Drug Development | Grant or award · Employee Stock Option (Right to Buy) | +76,362 | 76,362 | ||
| 2010-03-01 | Chadwick Jeremy G Sr. VP, Pgm Mgmt and Clin Ops | Grant or award | +7,908 | 23,761 | ||
| 2010-03-01 | Chadwick Jeremy G Sr. VP, Pgm Mgmt and Clin Ops | Grant or award · Employee Stock Option (Right to Buy) | +73,425 | 73,425 | ||
| 2010-03-01 | BAILEY MICHAEL P Sr. VP, Chief Comm. Officer | Grant or award | +8,627 | 33,627 | ||
| 2010-03-01 | BAILEY MICHAEL P Sr. VP, Chief Comm. Officer | Grant or award · Employee Stock Option (Right to Buy) | +80,100 | 80,100 | ||
| 2010-03-01 | Bahcall Safi R President and CEO | Grant or award | +13,839 | 2,306,586 | ||
| 2010-03-01 | Bahcall Safi R President and CEO | Grant or award · Employee Stock Option (Right to Buy) | +160,000 | 160,000 | ||
| 2010-01-08 | Kovner Bruce Director | Purchase | +550,000 | $4.50 | $2.5M | 1,500,673 |
| 2010-01-08 | WILSON ROBERT N Director | Purchase | +100,000 | $4.50 | $450K | 464,677 |
| 2010-01-08 | Gollust Keith R Director | Purchase | +100,000 | $4.50 | $450K | 164,079 |
| 2010-01-08 | Bahcall Safi R President and CEO | Purchase | +22,222 | $4.50 | $100K | 2,292,747 |
| 2009-08-24 | Koya Keizo Sr. VP, Drug Development | Purchase | +10,000 | $2.84 | $28K | 43,045 |
| 2009-08-06 | Chen Lin Huey 10% owner | Purchase | +20,000 | $2.88 | $58K | 620,035 |
| 2009-08-06 | Chen Lan Bo Director | Purchase | +20,000 | $2.88 | $58K | 620,035 |
| 2009-08-06 | Bahcall Safi R President and CEO | Purchase | +200 | $2.78 | $556 | 2,250,725 |
| 2009-08-06 | Bahcall Safi R President and CEO | Purchase | +6,079 | $2.80 | $17K | 2,256,804 |
| 2009-08-06 | Bahcall Safi R President and CEO | Purchase | +300 | $2.82 | $846 | 2,257,104 |
| 2009-08-06 | Bahcall Safi R President and CEO | Purchase | +1,980 | $2.83 | $6K | 2,259,084 |
| 2009-08-06 | Bahcall Safi R President and CEO | Purchase | +2,000 | $2.85 | $6K | 2,261,084 |
Page 77 of 82 · 1,629 trades